Bass Metals is one of many stocks the market is bullish on. Its expected double-digit top-line and bottom-line growth exceeds its peers, and its financially stable position lessens the chances of risk. If a buoyant growth prospect is what you’re after in your next investment, I’ve put together a list of high-growth stocks you may be interested in, based on the latest financial data from each company.

Bass Metals Limited (ASX:BSM)

Bass Metals Limited engages in graphite mining. The company provides employment to 130 people and with the company’s market capitalisation at AUD A$46.61M, we can put it in the small-cap group.

Driven by exceptional sales, which is expected to more than double over the next few years, BSM is expected to deliver an excellent earnings growth of 70.92%. Profit growth, coupled with top-line expansion, is a positive indication. This is because net income isn’t artificially inflated by unsustainable activities such as one-off cost-reductions expected in the future. BSM ticks the boxes for high-growth generation on all levels of line items, which makes it an appealing stock to dig into deeper. Should you add BSM to your portfolio? Check out its fundamental factors here.

Dacian Gold Limited (ASX:DCN)

Dacian Gold Limited explores and develops gold properties in Australia. Established in 2011, and now run by Rohan Williams, the company size now stands at 12 people and with the stock’s market cap sitting at AUD A$553.72M, it comes under the small-cap group.

DCN’s projected future profit growth is a robust 49.32%, with an underlying triple-digit growth from its revenues expected over the upcoming years. An affirming signal is when net income increase is supported by top-line growth. Since net income isn’t artificially inflated by one-off initiatives such as cost-cutting, we know this profit growth is more likely to be sustainable. We see this bottom-line expansion directly benefiting shareholders, with expected return on equity coming in at a notable 32.71%. DCN’s impressive outlook on all aspects makes it a worthy company to spend more time to understand. Considering DCN as a potential investment? Other fundamental factors you should also consider can be found here.

Medlab Clinical Limited (ASX:MDC)

Medlab Clinical Limited, a medical research and development facility, engages in nutraceutical products and pharmaceutical research businesses in Australia. Founded in 2012, and currently run by Sean Hall, the company employs 14 people and with the market cap of AUD A$172.66M, it falls under the small-cap stocks category.

MDC is expected to deliver an extremely high earnings growth over the next couple of years of 77.21%, bolstered by a significant revenue which is expected to more than double. It appears that MDC’s profitability may be sustainable as the fundamental push is top-line expansion rather than unmaintainable cost-cutting activities. This prospective profitability should trickle down to shareholders, with analysts expecting the company to generate a high double-digit return on equity of 86.87%. MDC ticks the boxes for high-growth generation on all levels of line items, which makes it an appealing stock to dig into deeper. Want to know more about MDC? Have a browse through its key fundamentals here.

For more financially robust companies with high growth potential to enhance your portfolio, use our free platform to explore our interactive list of these stocks.
To help readers see pass the short term volatility of the financial market, we aim to bring you a long-term focused research analysis purely driven by fundamental data. Note that our analysis does not factor in the latest price sensitive company announcements.

The author is an independent contributor and at the time of publication had no position in the stocks mentioned.